AveXis Inc. Names Director, Scientific and Corporate Affairs
Dallas, TX, September 13, 2013 --(PR.com)-- AveXis Inc. (avexisinc.com), a synthetic biology platform company, today announced Mindy Du as the company’s new Director of Scientific and Corporate Affairs.
This is an essential position within the company, as AveXis is focused on research/development of leading-edge technology for disease treatment. While Ms. Du stays involved in AveXis’ first focus in spinal muscular atrophy (SMA), she will continuously be searching for other collaborative opportunities with industry and academic partners to develop innovative treatment for other diseases with unmet medical needs.
Ms. Du comes to AveXis from BioLife Cell Bank. At BioLife, Ms. Du oversees operations and Food and Drug Administration documentation for its cGTP-compliant laboratory while conducting research for strategic business development projects and opportunities. Ms. Du formerly held research positions at the University of Texas Southwestern Medical Center, Department of Head and Neck Surgery, and the Massachusetts Institute of Technology (MIT), Department of Chemical Engineering. Her research experience includes tissue engineering with mesenchymal stem cells from umbilical tissue, biomechanical properties of vocal folds, and bioreactor design for antibody production in mammalian cells.
“I have worked with Mindy and overseen her laboratory for over a year now. I have watched her progress and personal growth first hand. Mindy is a rare individual who is both brilliant and has expertise in a very broad skill set. These skills come at a perfect time for our company. I am very happy to have her working directly with me. Coupled with our recent addition of Dr. Allan Kaspar as our Chief Scientific Officer, we have a formidable one-two punch aimed at SMA,” said John A. Carbona, Chief Executive Officer.
A graduate of MIT, Ms. Du earned Bachelor of Science degrees in both chemical-biological engineering and biology, while minoring in economics and management science.
For more information about AveXis: 1-855-9-AVEXIS or avexisinc.com.
About Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is an autosomal-recessive genetic disorder characterized by progressive weakness of the lower motor neurons. SMA is caused by a genetic defect in the SMN1 gene which codes SMN, a protein necessary for survival of motor neurons. SMA kills more infants than any other genetic disease in today's world.
About AveXis Inc.
Based in Dallas, Texas, AveXis is a synthetic biology platform company establishing unique industry alliances to create innovative treatments for people with unmet medical needs. Spinal muscular atrophy (SMA) is the company’s first focus.
Corporate Contact:
John A. Carbona, Chief Executive Officer
972-331-1905 or jc@avexisinc.com
Media Contact:
Jillian Bowman, Administrative Specialist
972-331-9626 or Jillianb@avexisinc.com
This is an essential position within the company, as AveXis is focused on research/development of leading-edge technology for disease treatment. While Ms. Du stays involved in AveXis’ first focus in spinal muscular atrophy (SMA), she will continuously be searching for other collaborative opportunities with industry and academic partners to develop innovative treatment for other diseases with unmet medical needs.
Ms. Du comes to AveXis from BioLife Cell Bank. At BioLife, Ms. Du oversees operations and Food and Drug Administration documentation for its cGTP-compliant laboratory while conducting research for strategic business development projects and opportunities. Ms. Du formerly held research positions at the University of Texas Southwestern Medical Center, Department of Head and Neck Surgery, and the Massachusetts Institute of Technology (MIT), Department of Chemical Engineering. Her research experience includes tissue engineering with mesenchymal stem cells from umbilical tissue, biomechanical properties of vocal folds, and bioreactor design for antibody production in mammalian cells.
“I have worked with Mindy and overseen her laboratory for over a year now. I have watched her progress and personal growth first hand. Mindy is a rare individual who is both brilliant and has expertise in a very broad skill set. These skills come at a perfect time for our company. I am very happy to have her working directly with me. Coupled with our recent addition of Dr. Allan Kaspar as our Chief Scientific Officer, we have a formidable one-two punch aimed at SMA,” said John A. Carbona, Chief Executive Officer.
A graduate of MIT, Ms. Du earned Bachelor of Science degrees in both chemical-biological engineering and biology, while minoring in economics and management science.
For more information about AveXis: 1-855-9-AVEXIS or avexisinc.com.
About Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is an autosomal-recessive genetic disorder characterized by progressive weakness of the lower motor neurons. SMA is caused by a genetic defect in the SMN1 gene which codes SMN, a protein necessary for survival of motor neurons. SMA kills more infants than any other genetic disease in today's world.
About AveXis Inc.
Based in Dallas, Texas, AveXis is a synthetic biology platform company establishing unique industry alliances to create innovative treatments for people with unmet medical needs. Spinal muscular atrophy (SMA) is the company’s first focus.
Corporate Contact:
John A. Carbona, Chief Executive Officer
972-331-1905 or jc@avexisinc.com
Media Contact:
Jillian Bowman, Administrative Specialist
972-331-9626 or Jillianb@avexisinc.com
Contact
AveXis Inc.
Jillian Bowman
972-331-9627
www.avexisinc.com
Jillian Bowman
972-331-9627
www.avexisinc.com
Contact
Categories